Regeneron Pharmaceuticals

REGN

1,091.19
USD
13.14
(1.22%)
Market Closed
Volume
45,513
EPS
0
Div Yield
0
P/E
26
Market Cap
106,775,369,480
Related Instruments
AMGN
2.78
(0.84%)
335.22 USD
B
BIIB
-2.500
(-1.17%)
210.710 USD
B
BMRN
0.270
(0.32%)
84.620 USD
GILD
0.470
(0.62%)
76.510 USD
I
ILMN
-0.250
(-0.20%)
122.370 USD
I
INCY
-0.680
(-1.05%)
64.390 USD
MRNA
-25.020
(-20.99%)
94.160 USD
News

Title: Regeneron Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Regeneron Pharmaceuticals Inc. is an integrated biotechnology firm. The company was founded in 1988 and is headquartered in Tarrytown, New York. It develops, manufactures and sells medicines for serious conditions such as eye diseases, allergy and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and more. Its product line includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST and ZALTRAP. The company was founded by Alfred G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988.